Stony Brook University receives significant investment for promising cancer medication development

Veröffentlicht:

Von: Natur.wiki Autoren-Team

Dr. Iwao Ojima entwickelt vielversprechendes Anti-Krebs-Mittel Reviewed by Emily Henderson, B.Sc. | Feb 28 2023 Für die letzten Jahrzehnte hat Dr. Iwao Ojima in seinem Labor am Department of Chemistry der Stony Brook University und am Institute of Chemical Biology & Drug Discovery (ICB&DD) daran gearbeitet, Anti-Krebs-Mittel der nächsten Generation zu entwickeln. Eines dieser Mittel, ein Taxan-Konjugat der zweiten Generation in nanoemulgierter Formulierung (NE-DHA-SBT-1214 genannt), hat sich als äußerst vielversprechend gegen solide Tumore erwiesen, insbesondere gegen Darmkrebs. Die Taxan-Verbindungen wurden 2016 an ein Spin-off-Unternehmen der Stony Brook University, TargaGenix, Inc., lizenziert, um ihre Entwicklung in Richtung klinische Anwendung voranzutreiben. Seitdem …
Dr. Iwao Ojima develops promising anti-cancer remedy reviewed by Emily Henderson, B.Sc. | Feb 28 2023 for the past decades Dr. Iwao Ojima in his laboratory at the Department of Chemistry at the Stony Brook University and at the Institute of Chemical Biology & Drug Discovery (ICB & DD) to develop the next generation anti-cancer. One of these means, a second generation of a second generation in nanoemulgated formulation (ne-DHA SBT-1214), has proven to be extremely promising against solid tumors, especially against colon cancer. The taxan connections were licensed to a spin-off company at Stony Brook University, Targagenix, Inc., in 2016 to drive their development towards clinical application. Since then ... (Symbolbild/natur.wiki)

dr. Iwao Ojima develops promising anti-cancer agents

Reviewed by Emily Henderson, B.Sc. | Feb 28 2023

For the past few decades, Dr. Iwao Ojima in his laboratory at the Department of Chemistry at the Stony Brook University and at the Institute of Chemical Biology & Drug Discovery (ICB & DD) to develop the next generation anti-cancer. One of these means, a second generation of a second generation in nanoemulgated formulation (ne-DHA SBT-1214), has proven to be extremely promising against solid tumors, especially against colon cancer. The taxan connections were licensed to a spin-off company at Stony Brook University, Targagenix, Inc., in 2016 to drive their development towards clinical application. Since then, Targagenix has further developed the connections, dealt with the wording, toxicity and effectiveness in vivo and attracted considerable investments in ne-dha-SBT-1214

Targagenix plans to develop the new Taxan as an independent medication with its partners and also use it in combination with other treatment methods, including immune-oncology funds. The company and its partners plan to promote the development of the drug in the near future into clinical testing on humans.

tvm Capital Life Science (TVM) provides up to $ 24 million for a development program to launch NE-DHA-SBT-124 as an alternative medication for the treatment of colon cancer and other solid tumors.

taxane are a class of cancer medication that is widely used to treat solid tumors. They include Paclitaxel, Docetaxel and Cabazitaxel. The medication class inhibits tumor growth by blocking the cell division of cancer cells. Multidrug resistance (MDR) as well as cancer stem cells (CSCs) and various side effects often make the effective use of these medication more difficult. Dr. Ojima and his team have developed a highly potent taxan of the second generation that is conjugated to DHA (a widespread nutritional supplement from omega-3 fatty acids) and is presented in nanoemulgated formulation. The medium (NE-DHA-SBT-1214) not only showed an excellent activity against MDR of solid tumor-xenograft models, but also in CSC-initiated tumor-xenograft models.

A main indication for NE-DHA-SBT-1214 is colon cancer, which is a very demanding type of cancer due to its strong multidrug resistance. But also in preclinical testing, the means shows promising results in pancreatic cancer and prostate cancer. For example, NE-DHA-SBT-1214 in combination with PLD-1 antibodies against pancreatic cancer was tested. Combination therapy showed better results than the currently best standard treatment against this fatal disease.

The new Taxan connection is formulated using a nanotechnology called Nanoemulsion, which originally by Dr. MANSOOR Amiji was developed at Northeastern University. Together with the DHA conjugation, this nano-formulation enables tumor-specific drug delivery through the so-called "Enhanced Permeability and Retention (EPR)" effect, which is characteristic of nano particles, as well as a controlled release of the highly-potent second generation. This was shown in preclinical tests and makes the taxan effectively against MDR and CSCs within the tumor.

"The newly developed taxan of Dr. Ojima and his team shows great success in preclinical studies on intestinal and pancreatic cancer, two of the most deadliest types of cancer in humans. After decades of research, we are pleased that the drug is now going through clinical studies on patients. This example illustrates the importance of research in the basic scientific departments of the Stony Book University for the development Potential cancer treatments, ”says Peter Igarashi, MD, Dean of the Renaissance School of Medicine at Stony Brook University.

"Taxane has been a cornerstone of cancer treatment for decades, but they can have considerable side effects, and treated cancer often occur again," says James E. Egan, CEO from Targagenix. "We are pleased about the strong support of TVM and about having the resources available for further development of this potentially groundbreaking molecule," adds Egan, who has achieved his doctorate in molecular pharmacology at Stony Brook University.

Stony Brooks University’s Intellectual Property Partners (IPP) worked closely with Targagenix to secure the investment of TVM.

"My office worked closely with James and TVM on this investment, and we are very happy about the end," says Sean Boykevisch, PhD, director of IPP. "The funding will drive this promising potential therapeutic in the clinic, where we hope that it will provide sensible clinical answers and may become a new treatment standard."

Source: Stony Brook University